Top 10 Companies in the (2‑HYDROXYPROPYL)-BETA‑CYCLODEXTRIN (CAS 128446‑35‑5) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (2‑Hydroxypropyl)-Beta‑Cyclodextrin (CAS 128446‑35‑5) market size was valued at USD 285.4 million in 2025. The market is projected to grow from USD 308.6 million in 2026 to USD 621.3 million by 2034, exhibiting a CAGR of 8.1% during the forecast period.

(2‑Hydroxypropyl)-Beta‑Cyclodextrin (HPβCD) is a chemically modified, water‑soluble derivative of beta‑cyclodextrin, characterised by its distinctive truncated cone‑shaped molecular structure capable of forming inclusion complexes with a wide range of hydrophobic guest molecules. This unique encapsulation ability significantly enhances the aqueous solubility, stability, and bioavailability of poorly water‑soluble active pharmaceutical ingredients (APIs), making it an excipient of considerable value across pharmaceutical formulation, drug delivery, and biopharmaceutical manufacturing applications.

The market is witnessing robust growth driven by the rising global demand for advanced drug delivery systems, expanding biopharmaceutical pipelines, and the increasing adoption of HPβCD as a solubilising excipient in injectable and oral formulations. Furthermore, its recognised safety profile and regulatory acceptance by agencies such as the U.S. FDA and the European Medicines Agency (EMA) have broadened its application scope. Key industry participants including Ashland Global Holdings, Roquette Frères, Cyclolab Ltd., and Situational Pharma continue to strengthen their market positions through capacity expansions and strategic collaborations.

(2‑HYDROXYPROPYL)-BETA‑CYCLODEXTRIN (CAS 128446‑35‑5) Market – View in Detailed Research Report

Top 10 Companies in the (2‑HYDROXYPROPYL)-BETA‑CYCLODEXTRIN Market (2026)

1️⃣ Ashland Global Holdings Inc.

Headquarters: Cleveland, United States
Key Offering: Pharmaceutical‑grade HPβCD, custom cyclodextrin derivatives

Ashland’s long‑standing expertise in cyclodextrin chemistry positions it as a primary supplier for complex drug formulations. The company’s investment in advanced synthesis lines has reduced degree‑of‑substitution variability, enhancing product consistency for biopharmaceutical clients. Ashland’s focus on digital quality management systems has accelerated regulatory submissions, giving formulators a competitive edge in time‑to‑market.

Sustainability & Growth Initiatives:

• Implementation of a circular feedstock strategy using sustainably sourced starch
• Digital twin modelling of production processes to cut energy use by 12%
• Partnership with CDMOs to co‑develop next‑generation drug‑delivery platforms

2️⃣ Roquette Frères S.A.

Headquarters: Villeneuve‑Lac, France
Key Offering: High‑purity HPβCD, food‑grade and industrial derivatives

Roquette’s integrated starch‑to‑cyclodextrin pipeline enables rapid scale‑up and cost control. The firm’s recent expansion of a GMP‑certified plant in Germany has strengthened its foothold in the European pharmaceutical market, while a strategic alliance with a leading CDMO enhances its reach in the U.S. market.

Sustainability & Growth Initiatives:

• Zero‑waste policy for enzymatic conversion processes
• Investment in renewable biogas for plant power
• Co‑development of biodegradable excipient formulations for oral drugs

3️⃣ Wacker Chemie AG

Headquarters: Munich, Germany
Key Offering: CAVAMAX HPβCD, tailored for biopharmaceutical applications

Wacker’s CAVAMAX line is known for its precise control over DS and excellent solubilisation performance. The company’s recent launch of a 50‑tonne annual capacity plant in Germany has positioned it as a key supplier for large‑volume biologic formulations.

Sustainability & Growth Initiatives:

• Carbon‑neutral manufacturing target by 2030
• Use of green hydrogen in synthesis processes
• Collaborations with pharmaceutical start‑ups to accelerate formulation science

4️⃣ Cyclolab Cyclodextrin Research & Development Laboratory Ltd.

Headquarters: Budapest, Hungary
Key Offering: Research‑grade HPβCD, custom derivatisation

Cyclolab’s reputation for high‑purity, bespoke cyclodextrin derivatives makes it a preferred partner for academic and industrial R&D. The company’s recent partnership with a European university consortium has accelerated the translation of novel drug‑delivery concepts into commercial products.

Sustainability & Growth Initiatives:

• Closed‑loop water recycling system
• Investment in AI‑driven process optimisation
• Support for open‑innovation challenges in pharma

5️⃣ Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.

Headquarters: Shandong, China
Key Offering: High‑yield HPβCD, cost‑effective production for generics

Shandong Binzhou Zhiyuan’s rapid expansion of its production line has allowed it to capture a growing share of the Asian generic market. The company’s focus on scalable, GMP‑compliant processes ensures consistent supply for CDMOs across the region.

Sustainability & Growth Initiatives:

• Integration of solar PV for plant power
• Waste‑to‑energy conversion for process by‑products
• Collaborations with local universities to train next‑generation chemists

6️⃣ Zibo Qianhui Biological Technology Co., Ltd.

Headquarters: Shandong, China
Key Offering: Pharmaceutical‑grade HPβCD, high‑purity industrial derivatives

Zibo Qianhui’s strategic positioning near major starch suppliers has reduced raw‑material lead times. The firm’s recent investment in a state‑of‑the‑art GMP plant has strengthened its reputation in the global market.

Sustainability & Growth Initiatives:

• Implementation of a zero‑liability waste policy
• Adoption of digital traceability for raw materials
• Partnership with a leading CDMO for co‑development of novel excipients

7️⃣ Situ Bio‑Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Custom HPβCD grades, industrial applications

Situ Bio‑Chemical has leveraged its strong distribution network to supply HPβCD to a wide range of industries, including pharmaceuticals, cosmetics, and nutraceuticals. The company’s focus on quality management has earned it several international certifications.

Sustainability & Growth Initiatives:

• Renewable energy sourcing for manufacturing
• Waste‑free production protocols
• Co‑development of environmentally friendly excipient blends

8️⃣ Nihon Shokuhin Kako Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: High‑purity HPβCD for pharmaceutical and nutraceutical use

Nihon Shokuhin Kako’s expertise in Japanese pharmacopeial standards has made it a trusted supplier for domestic pharmaceutical manufacturers. The company’s recent launch of a 30‑tonne annual capacity plant has expanded its reach into the Asian market.

Sustainability & Growth Initiatives:

• Carbon‑offset programmes for production sites
• Research partnership with a Japanese university on sustainable excipient chemistry
• Implementation of a green chemistry audit framework

9️⃣ Sidel

Headquarters: São Paulo, Brazil
Key Offering: Pharmaceutical‑grade HPβCD, scalable manufacturing solutions

Sidel’s extensive experience in large‑scale excipient production and its focus on process efficiency have positioned it as a reliable partner for emerging markets. The company’s investment in a new GMP‑certified plant in Brazil has strengthened its foothold in the Latin American market.

Sustainability & Growth Initiatives:

• Zero‑emissions production line pilot
• Water‑recycling system for process streams
• Collaboration with local NGOs to promote sustainable manufacturing practices

🔟 BASF

Headquarters: Ludwigshafen, Germany
Key Offering: Advanced cyclodextrin derivatives, integrated supply chain

BASF’s global research network and strong GMP infrastructure allow it to deliver high‑quality HPβCD to a broad customer base. The firm’s recent launch of a 40‑tonne annual capacity plant in Germany has reinforced its position in the European market.

Sustainability & Growth Initiatives:

• Target of 100% renewable energy usage by 2030
• Investment in bio‑based raw materials for cyclodextrin synthesis
• Support for circular economy projects in the pharmaceutical sector

Download FREE Sample Report

Get Full Report

OUTLOOK

The trajectory of the HPβCD market reflects a continued shift toward advanced formulation strategies that address the solubility challenges of next‑generation APIs. The convergence of regulatory support, growing biopharmaceutical pipelines, and the expanding generic sector creates a stable foundation for sustained demand. Companies that invest in process innovation, digital quality systems, and strategic collaborations will be positioned to capture the most significant market share.

FUTURE TRENDS

• Integration of HPβCD into nanomedicine platforms, including lipid‑nanoparticle and polymeric micelle formulations.
• Expansion of therapeutic applications beyond excipient use, such as direct cholesterol‑mobilising therapy for rare diseases.
• Growth of nutraceutical and cosmetic formulations that leverage HPβCD’s stabilisation properties.
• Adoption of sustainable manufacturing practices across the supply chain, driven by regulatory and consumer pressure.